A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

• Status: Recruiting
• Trial end date: 2023-06-01

Summary

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: Janssen Pharmaceuticals
• Treatments: Antibodies, Monoclonal; BB 1101; Daratumumab; Dexamethasone; Dexamethasone acetate; Lenalidomide; Thalidomide